Titan BiotechBOM:524717 +4.99%50 ROE % is 14.83% as of Mar. 2026, which is 21% below its 10-year median of 18.82. GuruFocus rates BOM:524717 with a GF Score™ of 50/100 and a GF Value™ of ₹144.35 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,250 Biotechnology companies, Titan Biotech ranks better than 92.16% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Titan Biotech's annualized net income for the quarter that ended in Mar. 2026 was ₹269 Mil. Titan Biotech's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹1,815 Mil. Therefore, Titan Biotech's annualized ROE % for the quarter that ended in Mar. 2026 was 14.83%.
The historical rank and industry rank for Titan Biotech's ROE % or its related term are showing as below:
BOM:524717'
s ROE % Range Over the Past 10 Years
Min: 9.79 Med: 18.82 Max: 56.2
Current: 17.88
During the past 13 years, Titan Biotech's highest ROE % was 56.20%. The lowest was 9.79%. And the median was 18.82%.
BOM:524717's ROE % is ranked better than 92.16% of 1250
companies
in the Biotechnology industry
Industry Median: -38.26
vs BOM:524717: 17.88
Titan Biotech (BOM:524717) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Titan Biotech ROE % Related Terms
Titan Biotech ROE % Historical Data
* Premium members only.
The historical data trend for Titan Biotech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Titan Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's ROE % distribution charts can be found below:
* The bar in red indicates where Titan Biotech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Titan Biotech (BOM:524717) has a ROE % of 14.83% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Titan Biotech and its competitors. This is 21% below median its historical median of 18.82. Over the past decade, Titan Biotech's ROE % has ranged from 9.79 to 56.20. According to the industry distribution chart, Titan Biotech ranks #98 out of 1250 companies in the Biotechnology industry, placing it in the top 7.8%.
Is Titan Biotech's ROE % too high?
Titan Biotech's current ROE % of 14.83% is 21% below median its 10-year median of 18.82. Over the past 10 years, this metric has ranged from a low of 9.79 to a high of 56.20. Based on the distribution chart, Titan Biotech ranks #98 out of 1250 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Titan Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #98 out of 1250 companies for ROE %. This places Titan Biotech in the top 8% of its industry — outperforming the majority of peers. Historically, Titan Biotech's own ROE % has ranged from 9.79 to 56.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Titan Biotech and its competitors. Titan Biotech's current ROE % is 14.83%, which is 21% below median its own 10-year median of 18.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.35, compared to a current price of ₹389.10 — trading 169.6% above its estimated fair value. The current ROE % is 14.83%, which is 21% below median its 10-year median of 18.82. Titan Biotech's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current ROE % is 14.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹389.10 is trading 169.6% above its estimated GF Value™ of ₹144.35.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
ROE %: 14.83% (21% below median its 10-year median of 18.82)
GF Value™: ₹144.35 vs. price of ₹389.10 (169.6% above fair value)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
50GF Score
Get the complete analysis for BOM:524717
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
